iBio, Inc. (IBIO)
NASDAQ: IBIO · Real-Time Price · USD
0.8800
-0.0146 (-1.63%)
Sep 16, 2025, 11:17 AM EDT - Market open
iBio, Inc. Employees
iBio, Inc. had 16 employees as of June 30, 2024. The number of employees decreased by 10 or -38.46% compared to the previous year.
Employees
16
Change (1Y)
-10
Growth (1Y)
-38.46%
Revenue / Employee
$25,000
Profits / Employee
-$1,148,563
Market Cap
17.30M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Jun 30, 2024 | 16 | -10 | -38.46% |
Jun 30, 2023 | 26 | -80 | -75.47% |
Jun 30, 2022 | 106 | 31 | 41.33% |
Jun 30, 2021 | 75 | 24 | 47.06% |
Jun 30, 2020 | 51 | -4 | -7.27% |
Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
IBIO News
- 11 days ago - iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 22 days ago - iBio Announces Closing of $50 Million Public Offering - GlobeNewsWire
- 4 weeks ago - iBio Announces Pricing of $50 Million Public Offering - GlobeNewsWire
- 4 weeks ago - iBio Announces Proposed Public Offering - GlobeNewsWire
- 3 months ago - iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results - GlobeNewsWire
- 3 months ago - iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call - GlobeNewsWire
- 3 months ago - iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment - GlobeNewsWire
- 4 months ago - iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model - GlobeNewsWire